We are live on
!
Find out more
Boston Partners Portfolio holdings
AUM
$113B
1-Year Est. Return
38.87%
This Fund
S&P 500
This Quarter
Est. Return
+2.73%
1 Year Est. Return
+38.87%
3 Year Est. Return
+108.29%
5 Year Est. Return
+142.95%
10 Year Est. Return
+500.61%
AUM
$67.2B
AUM Growth
+$540M
(+0.81%)
Cap. Flow
-$425M
Cap. Flow
% of AUM
-0.63%
Top 10 Holdings %
Top 10 Hldgs %
16.83%
Holding
780
New
63
Increased
245
Reduced
379
Closed
79
Avg Time Held
5.2
quarters
Top 10 Avg Time Held
4.8
quarters
Top 20 Avg Time Held
4.3
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$840M |
| 2 |
RTX Corp
RTX
|
+$638M |
| 3 |
Trane Technologies
TT
|
+$326M |
| 4 |
Anadarko Petroleum
APC
|
+$299M |
| 5 |
Gilead Sciences
GILD
|
+$274M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Citigroup
C
|
+$489M |
| 2 |
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
|
+$397M |
| 3 |
ExxonMobil
XOM
|
+$325M |
| 4 |
Comcast
CMCSA
|
+$322M |
| 5 |
TWX
Time Warner Inc
TWX
|
+$293M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 24.95% |
| 2 | Healthcare | 16.68% |
| 3 | Technology | 16.63% |
| 4 | Industrials | 11.82% |
| 5 | Consumer Discretionary | 8.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
JPMorgan Chase
JPM
$889B
| $1.5B | 2.23% |
24,694,020
-1,204,598
| -5% | -$71.3M |
2013 Q2
7 quarters
|
|
2
Wells Fargo
WFC
$252B
| $1.34B | 1.99% |
24,583,186
-3,098,539
| -11% | -$167M |
2013 Q2
7 quarters
|
|
3
Berkshire Hathaway Class B
BRK.B
$1.11T
| $1.27B | 1.89% |
8,776,188
-194,178
| -2% | -$28.6M |
2013 Q2
7 quarters
|
|
4
Capital One
COF
$123B
| $1.24B | 1.85% |
15,785,254
-243,371
| -2% | -$19.1M |
2013 Q2
7 quarters
|
|
5
Pfizer
PFE
$162B
| $1.14B | 1.7% |
34,665,429
-4,025,962
| -10% | -$128M |
2013 Q2
7 quarters
|
|
|
6
Citigroup
C
$221B
| $1.04B | 1.54% |
20,105,947
-9,608,686
| -32% | -$489M |
2013 Q2
7 quarters
|
|
7
Apple
AAPL
$4.98T
| $1B | 1.49% |
32,248,316
-462,432
| -1% | -$14M |
2013 Q2
7 quarters
|
|
8
Johnson & Johnson
JNJ
$636B
| $970M | 1.44% |
9,640,931
-702,108
| -7% | -$71.4M |
2013 Q2
7 quarters
|
|
9
Allstate
ALL
$58.8B
| $912M | 1.36% |
12,815,845
+43,763
| +0.3% | +$3.09M |
2013 Q3
6 quarters
|
|
10
Medtronic
MDT
$118B
| $896M | 1.33% |
11,493,847
+3,342,279
| +41% | +$253M |
2013 Q2
7 quarters
|
|
11
CVS Health
CVS
$112B
| $893M | 1.33% |
8,649,516
-558,525
| -6% | -$56.5M |
2013 Q2
7 quarters
|
|
12
Cisco
CSCO
$455B
| $881M | 1.31% |
32,010,491
-1,278,246
| -4% | -$36M |
2013 Q2
7 quarters
|
|
|
13
Merck
MRK
$359B
| $814M | 1.21% |
+14,837,117
| New | +$840M |
2015 Q1
0 quarters
|
|
14
Microsoft
MSFT
$4.02T
| $802M | 1.19% |
19,732,706
+115,477
| +0.6% | +$5.03M |
2013 Q2
7 quarters
|
|
15
Phillips 66
PSX
$112B
| $767M | 1.14% |
9,761,720
-93,222
| -0.9% | -$6.84M |
2013 Q2
7 quarters
|
|
16
DELISTED
EMC CORPORATION
EMC
| $764M | 1.14% |
29,885,737
-966,286
| -3% | -$26.6M |
2013 Q2
7 quarters
|
|
|
ESRX
17
DELISTED
Express Scripts Holding Company
ESRX
| $745M | 1.11% |
8,580,771
-316,451
| -4% | -$26.5M |
2013 Q2
7 quarters
|
|
18
Western Digital
WDC
$145B
| $683M | 1.02% |
9,935,913
+951,936
| +11% | +$74.4M |
2013 Q2
7 quarters
|
|
19
Oracle
ORCL
$416B
| $679M | 1.01% |
15,746,620
-1,035,177
| -6% | -$44.9M |
2013 Q2
7 quarters
|
|
|
ATVI
20
DELISTED
Activision Blizzard
ATVI
| $679M | 1.01% |
29,874,466
-162,863
| -0.5% | -$3.57M |
2013 Q2
7 quarters
|
|
|
21
RTX Corp
RTX
$252B
| $670M | 1% |
9,084,876
+8,536,096
| +1,555% | +$638M |
2013 Q2
7 quarters
|
|
22
Liberty Global Class C
LBTYK
$2.86B
| $666M | 0.99% |
16,521,302
+67,476
| +0.4% | +$2.67M |
2013 Q2
7 quarters
|
|
23
Lockheed Martin
LMT
$118B
| $650M | 0.97% |
3,204,973
-109,274
| -3% | -$21.6M |
2013 Q2
7 quarters
|
|
24
Lear
LEA
$5.78B
| $634M | 0.94% |
5,723,609
-555,653
| -9% | -$58.4M |
2013 Q2
7 quarters
|
|
25
TE Connectivity
TEL
$62.9B
| $634M | 0.94% |
8,851,224
-838,073
| -9% | -$57.6M |
2013 Q2
7 quarters
|
|
Similar funds
Boston Partners's Q1 2015 Portfolio in Review
As of Q1 2015, Boston Partners held 780 positions worth $67.2B, up 0.81% from $66.6B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Boston Partners's Q1 2015 filing shows 63 new, 245 increased, 379 reduced and 79 closed positions. Its largest new stake was Merck: 14,837,117 shares worth $814M. The largest sale was Citigroup, an estimated $489M.
By sector, the portfolio is most concentrated in Financials at 25% of assets, down from 27% a quarter earlier, followed by Healthcare and Technology.
- Boston Partners's largest Q1 2015 buy was Merck: 14,837,117 shares worth $814M.
- Boston Partners added most to RTX Corp in Q1 2015, an estimated $638M increase.
- Boston Partners's biggest Q1 2015 reduction was Citigroup, cutting an estimated $489M.
- Boston Partners fully exited COVIDIEN PLC COM SHS NEW (IRELAND) in Q1 2015, selling an estimated $397M.
- Boston Partners's ten largest holdings make up 17% of its $67.2B portfolio in Q1 2015.
- Boston Partners opened 63 new positions and closed 79 in Q1 2015.
- Boston Partners's portfolio value rose 0.81% quarter-over-quarter to $67.2B.
Based on Boston Partners's 13F filing for Q1 2015, filed 5 May 2015.